Briefly Bio
PrivateLast Round
Pre Seed
Jul 17, 2024
Total Funding Raised
$1.2M
Company Overview
Briefly Bio operates in Healthcare & Life Sciences and is based in London. Its latest recorded funding round was a Pre Seed round in July 2024.
Briefly Bio is a biotechnology company that provides an AI-powered experiment builder and collaborative platform to help scientists design, standardize, and share laboratory protocols.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Workflow Automation, Document Management, Vertical SaaS, NLP & Conversational AI
Business Model
B2B
Customer Profile
Subscription SaaS, Freemium
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Briefly Bio Comparables
Compare Briefly Bio with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Benchling | 76% | |
| Springer Nature | 76% | |
| Scispot | 75% |
For institutional investors. Book with your work email.
Briefly Bio Funding Rounds
Historical fundraising activity
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Briefly Bio Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Tiny Supercomputer Investment Company | Pre Seed |
| NP-Hard Ventures | Pre Seed |
| The Compound Capital Fund | Pre Seed |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jun 17, 2026
Monthly visitors grew 66% MoM, from 1.6K to 2.7K.
- Apr 16, 2026
Monthly visitors increased 46% MoM, reaching 2K.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- partners_withAug 17, 2026
In Feb '26, Briefly begins working with Aria and Syntato to improve plant cell transformation efficiency through autonomous AI-led experiments.
- partners_withAug 17, 2026
In Feb '26, Briefly partners with Syntato to improve the efficiency of plant cell transformation by agrobacteria through autonomous AI Scientist experiments conducted by lab robots.
For institutional investors. Book with your work email.
Briefly Bio Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Briefly Bio's valuation, stock price, and market status.
Is Briefly Bio a public or private company?
Briefly Bio is a private company.
What is the current stock price of Briefly Bio?
Briefly Bio is a private company, so its shares have no public market price. Caplight tracks Briefly Bio's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Briefly Bio worth (valuation)?
Valuation information for Briefly Bio is not publicly available.
Can I buy Briefly Bio stock?
Briefly Bio shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Briefly Bio's last funding round?
Briefly Bio's most recent funding round was Pre Seed on July 17, 2024.
Who are the main investors in Briefly Bio?
Key investors in Briefly Bio include The Compound Capital Fund.
Will Briefly Bio IPO soon?
No public IPO plans have been announced for Briefly Bio.
How can I track Briefly Bio secondary market activity?
Caplight tracks bids, offers, and trades in Briefly Bio's shares on secondary markets.